| Primary |
| Hypertension |
23.5% |
| Type 2 Diabetes Mellitus |
11.8% |
| Hyperphosphataemia |
8.8% |
| Calcium Phosphate Product |
5.9% |
| Hyperlipidaemia |
5.9% |
| Osteoporosis Prophylaxis |
5.9% |
| Prophylaxis |
5.9% |
| Renal Failure |
5.9% |
| Bladder Cancer |
2.9% |
| Blood Calcium Decreased |
2.9% |
| Blood Phosphorus Increased |
2.9% |
| Bone Disorder |
2.9% |
| Hyperuricaemia |
2.9% |
| Prostate Cancer |
2.9% |
| Renal Failure Chronic |
2.9% |
| Unevaluable Event |
2.9% |
| Urethral Cancer |
2.9% |
|
| Foreign Body Aspiration |
11.8% |
| Nausea |
11.8% |
| Blood Calcium Decreased |
5.9% |
| Circulatory Collapse |
5.9% |
| Confusional State |
5.9% |
| Constipation |
5.9% |
| Diarrhoea |
5.9% |
| Hypercalcaemia |
5.9% |
| Intestinal Calcification |
5.9% |
| Lip Swelling |
5.9% |
| Medication Residue |
5.9% |
| No Therapeutic Response |
5.9% |
| Pain In Extremity |
5.9% |
| Pyrexia |
5.9% |
| Vomiting |
5.9% |
|
| Secondary |
| Drug Use For Unknown Indication |
45.2% |
| Product Used For Unknown Indication |
14.9% |
| Rheumatoid Arthritis |
8.3% |
| Pyrexia |
6.0% |
| B Precursor Type Acute Leukaemia |
4.8% |
| Anxiety Disorder |
2.4% |
| Osteoporosis |
2.4% |
| Basedow's Disease |
1.8% |
| Blood Phosphorus Increased |
1.8% |
| Hyperparathyroidism Secondary |
1.8% |
| Pulmonary Embolism |
1.8% |
| Venous Thrombosis |
1.8% |
| Acute Promyelocytic Leukaemia |
1.2% |
| Blood Calcium Decreased |
1.2% |
| Osteoporosis Prophylaxis |
1.2% |
| Somatic Delusion |
1.2% |
| Anticoagulant Therapy |
0.6% |
| Antifungal Prophylaxis |
0.6% |
| Constipation |
0.6% |
| Gastritis |
0.6% |
|
| Tuberculosis |
27.8% |
| Diarrhoea |
8.3% |
| Calcium Deficiency |
5.6% |
| Confusional State |
5.6% |
| Pulmonary Calcification |
5.6% |
| Somnolence |
5.6% |
| Vomiting |
5.6% |
| Abdominal Pain |
2.8% |
| Blood Creatine Phosphokinase Increased |
2.8% |
| Completed Suicide |
2.8% |
| Depression |
2.8% |
| Drug Withdrawal Syndrome |
2.8% |
| Encephalopathy |
2.8% |
| Gastric Ulcer Haemorrhage |
2.8% |
| Hypophosphataemia |
2.8% |
| Middle Insomnia |
2.8% |
| Necrosis |
2.8% |
| Nephrolithiasis |
2.8% |
| Pain In Extremity |
2.8% |
| Progressive Multifocal Leukoencephalopathy |
2.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
47.1% |
| Drug Use For Unknown Indication |
19.7% |
| Hypertension |
5.5% |
| Hyperparathyroidism Secondary |
2.7% |
| Osteoporosis |
2.6% |
| Pain |
2.3% |
| Renal Failure Chronic |
2.1% |
| Rheumatoid Arthritis |
2.0% |
| Nuclear Magnetic Resonance Imaging |
1.6% |
| Peritoneal Dialysis |
1.6% |
| Diabetes Mellitus |
1.5% |
| Prophylaxis |
1.5% |
| Blood Cholesterol Increased |
1.5% |
| Vitamin Supplementation |
1.4% |
| Supplementation Therapy |
1.3% |
| Anaemia |
1.3% |
| Crohn's Disease |
1.2% |
| Renal Failure |
1.1% |
| Hyperphosphataemia |
1.1% |
| Infection |
0.9% |
|
| Flushing |
13.8% |
| Vomiting |
8.6% |
| Therapeutic Response Decreased |
6.1% |
| Sepsis |
5.8% |
| Haemoglobin Decreased |
5.6% |
| Pruritus |
5.4% |
| Death |
5.1% |
| Nephrogenic Systemic Fibrosis |
4.7% |
| Renal Failure |
4.7% |
| Rhabdomyolysis |
4.4% |
| Nausea |
4.2% |
| Tumour Lysis Syndrome |
4.2% |
| Rash |
4.0% |
| Anaemia |
3.7% |
| Pain |
3.5% |
| Thrombocytopenia |
3.5% |
| Drug Ineffective |
3.3% |
| Dyspnoea |
3.3% |
| Paraesthesia |
3.3% |
| Nephrogenic Fibrosing Dermopathy |
2.8% |
|
| Interacting |
| Product Used For Unknown Indication |
91.7% |
| Renal Failure Chronic |
8.3% |
|
| Drug Interaction |
50.0% |
| No Adverse Event |
50.0% |
|
